KRAS and neoplasm: Examples include the MEK inhibitors selumetinib and binimetinib in KRAS mutant non-small cell lung cancer11 and NRAS- or BRAF-mutated melanoma12, respectively, as well as phosphatidyl inositol 3-kinase (PI3K) pathway inhibitors for multiple PI3K mutant tumour types13.